Parkinson's Disease
Conditions
Keywords
dyskinesia, movement disorders, basal ganglia diseases, JP-1730, Parkinson, end-of-dose wearing off, fluctuations
Brief summary
The purpose of this study is to determine whether Fipamezole is effective in the treatment of levodopa-induced dyskinesia in advanced Parkinson's disease.
Detailed description
This study is a multi-center, double-blind, placebo-controlled, multiple dose escalating, safety, tolerance, pharmacokinetics, and efficacy study of fipamezole administered in Parkinson's disease patients who are concomitantly being treated with a combination product of levodopa with a dopamine decarboxylase inhibitor (DDI) and possible other antiparkinson medication. Approximately 30 sites in the US and India will participate in this study. The patients will be randomized into one of four treatment arms to receive either fixed or ascending doses of Fipamezole (from 30 to 90 mg tid) or placebo. For efficacy assessments, levodopa-induced dyskinesia is assessed using a standardised rating scale. Time spent in 'Off' state or in 'On' state without dyskinesia, 'On' with non-troublesome dyskinesia or 'On' with troublesome dyskinesia, is assessed using patient diaries. Impact of dyskinesia on daily activities is quantified using a PDYS-26 questionnaire. To explore potential positive or negative impact of Fipamezole on cognitive functions, the study includes two cognitive tests. Finally, the study includes investigator assessments of CGI-I scales for dyskinesia, Parkinson's disease, and clinical condition in general.
Interventions
DRUGfipamezole
Fipamezole in Zydis formulation three times per day for up to 28 days
Sponsors
Santhera Pharmaceuticals
Juvantia Pharma Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Main Inclusion Criteria: * Idiopathic Parkinson's disease. * Levodopa/DDI associated peak-dose dyskinesia which is at least moderately disabling and present for ≥25% of the waking day (UPDRS part IV, items 32 and 33, each ≥ 2). * Stable Parkinson's medication for at least 1 month prior to randomization. * Hoehn and Yahr Stages 1 to 4 during 'Off' period. * Demonstrated ability to comprehend and give informed consent. * Ability to complete patient diary. Main
Exclusion criteria
* Other clinically significant conditions apart from those typically associated with Parkinson's disease. * Intake of medication associated with exacerbation of dyskinesia or with extrapyramidal side effects and tardive dyskinesia or induction of liver enzymes; neuroleptics; or specified drugs known to be substantially metabolized through the following cytochrome P450 isoenzymes: 1A2, 2B6, 2C19, 2C9, 2D6, and 2E1. * Use of St. John's Wort or Ginkgo Biloba within 48 hrs prior to randomization and until the last treatment day with the study medication. * Intake of an investigational drug within 30 days prior to initial screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the efficacy of 3 different doses of fipamezole with that of placebo on dyskinesia as assessed by a dyskinesia assessment scale. | 28-days treatment |
Secondary
| Measure | Time frame |
|---|---|
| To compare efficacy of 3 different doses of fipamezole with that of placebo on the mean daily 'Off' time, as recorded in the patient diary. | 28-days treatment |
Countries
India, United States
Outcome results
None listed